-
AbbVie Q3 2024 Financial statements
Financial statements
In Q3 2024, AbbVie reported net revenues of $14.460 billion, a 3.8% year-on-year increase. Skyrizi surged by 50.8% to $3.205 billion, offsetting Humira's decline due to generics. Diverse segments, including Oncology and Neuroscience, showed solid growth, while strategic acquisitions.
五寨县|
尼木县|
山东省|
潍坊市|
巴林右旗|
双鸭山市|
甘泉县|
六安市|
西畴县|
仙游县|
资阳市|
达拉特旗|
南岸区|
乐亭县|
济源市|
长白|
信丰县|
泸西县|
原平市|
武穴市|
石泉县|
迁西县|
遂昌县|
汝城县|
秦安县|
怀来县|
盱眙县|
临沂市|
利川市|
铜川市|
屏边|
临汾市|
嵊州市|
开封市|
郧西县|
六枝特区|
噶尔县|
轮台县|
古浪县|
泸水县|
剑河县|